Javascript must be enabled to continue!
The complex role of kininogens in hereditary angioedema
View through CrossRef
Human high molecular weight kininogen (HK) is the substrate from which bradykinin is released as a result of activation of the plasma “contact” system, a cascade that includes the intrinsic coagulation pathway, and a fibrinolytic pathway leading to the conversion of plasminogen to plasmin. Its distinction from low molecular weight kininogen (LK) was first made clear in studies of bovine plasma. While early studies did suggest two kininogens in human plasma also, their distinction became clear when plasma deficient in HK or both HK and LK were discovered. The light chain of HK is distinct and has the site of interaction with negatively charged surfaces (domain 5) plus a 6th domain that binds either prekallikrein or factor XI. HK is a cofactor for multiple enzymatic reactions that relate to the light chain binding properties. It augments the rate of conversion of prekallikrein to kallikrein and is essential for the activation of factor XI. It indirectly augments the “feedback” activation of factor XII by plasma kallikrein. Thus, HK deficiency has abnormalities of intrinsic coagulation and fibrinolysis akin to that of factor XII deficiency in addition to the inability to produce bradykinin by factor XII-dependent reactions. The contact cascade binds to vascular endothelial cells and HK is a critical binding factor with binding sites within domains 3 and 5. Prekallikrein (or factor XI) is attached to HK and is brought to the surface. The endothelial cell also secretes proteins that interact with the HK-prekallikrein complex resulting in kallikrein formation. These have been identified to be heat shock protein 90 (HSP 90) and prolylcarboxypeptidase. Cell release of urokinase plasminogen activator stimulates fibrinolysis. There are now 6 types of HAE with normal C1 inhibitors. One of them has a mutated kininogen but the mechanism for overproduction (presumed) of bradykinin has not yet been determined. A second has a mutation involving sulfation of proteoglycans which may lead to augmented bradykinin formation employing the cell surface reactions noted above.
Title: The complex role of kininogens in hereditary angioedema
Description:
Human high molecular weight kininogen (HK) is the substrate from which bradykinin is released as a result of activation of the plasma “contact” system, a cascade that includes the intrinsic coagulation pathway, and a fibrinolytic pathway leading to the conversion of plasminogen to plasmin.
Its distinction from low molecular weight kininogen (LK) was first made clear in studies of bovine plasma.
While early studies did suggest two kininogens in human plasma also, their distinction became clear when plasma deficient in HK or both HK and LK were discovered.
The light chain of HK is distinct and has the site of interaction with negatively charged surfaces (domain 5) plus a 6th domain that binds either prekallikrein or factor XI.
HK is a cofactor for multiple enzymatic reactions that relate to the light chain binding properties.
It augments the rate of conversion of prekallikrein to kallikrein and is essential for the activation of factor XI.
It indirectly augments the “feedback” activation of factor XII by plasma kallikrein.
Thus, HK deficiency has abnormalities of intrinsic coagulation and fibrinolysis akin to that of factor XII deficiency in addition to the inability to produce bradykinin by factor XII-dependent reactions.
The contact cascade binds to vascular endothelial cells and HK is a critical binding factor with binding sites within domains 3 and 5.
Prekallikrein (or factor XI) is attached to HK and is brought to the surface.
The endothelial cell also secretes proteins that interact with the HK-prekallikrein complex resulting in kallikrein formation.
These have been identified to be heat shock protein 90 (HSP 90) and prolylcarboxypeptidase.
Cell release of urokinase plasminogen activator stimulates fibrinolysis.
There are now 6 types of HAE with normal C1 inhibitors.
One of them has a mutated kininogen but the mechanism for overproduction (presumed) of bradykinin has not yet been determined.
A second has a mutation involving sulfation of proteoglycans which may lead to augmented bradykinin formation employing the cell surface reactions noted above.
Related Results
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review
Angioedema is a health issue that affects parts of the body like the upper pulmonary
and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous me...
DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
The patient is a 69-year-old male with a past medical history of intellectual disability, hypertension, type 2 diabetes mellitus, and angiotensin-converting enzyme (ACE) inhibitor–...
Hereditary Angioedema: From Gene to Gene Therapy
Hereditary Angioedema: From Gene to Gene Therapy
Abstract
Hereditary angioedema (HAE) (OMIM #106100) is a rare genetic, autosomal dominant condition characterised by recurrent, u...
Angioedema com Uso de Enalapril: Relato de Caso
Angioedema com Uso de Enalapril: Relato de Caso
Os inibidores da enzima conversora de angiotensina (IECA) são drogas amplamente usadas na cardiologia. Seu efeito adverso mais potencialmente grave é o angioedema. Embora raro, tem...
Malignancy and Immune Disorders in Patients With Hereditary Angioedema
Malignancy and Immune Disorders in Patients With Hereditary Angioedema
Abstract
Background
With the advent of new therapies, patients with hereditary angioedema (HAE) are living longer lives. Although complement dysregulation has been linked ...
Angioedema y lupus eritematoso sistémico: ¿Una asociación inusual o poco sospechada?
Angioedema y lupus eritematoso sistémico: ¿Una asociación inusual o poco sospechada?
Según la Organización Mundial de Alergia, el angioedema se caracteriza por una reacción vascular transitoria de los tejidos dérmicos- subcutáneos profundos o de los tejidos mucosos...
Anestesia em Paciente com Angioedema Hereditário
Anestesia em Paciente com Angioedema Hereditário
Introdução: O angioedema hereditário (AEH) é uma doença genética autossômica dominante caracterizada por deficiência da enzima inibidora de C1-esterase (C1-INH). Na via inflamatóri...

